Literature DB >> 3080220

Chemotherapy of malignant thymoma. Case report and review of the literature.

E Hu, J Levine.   

Abstract

The authors report the case of a patient with malignant thymoma unresponsive to combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] and cisplatin/VP-16) who subsequently achieved clinical response to continuous daily prednisone. A review of the literature indicates that prednisone and cisplatin are the most active agents in the treatment of malignant thymoma.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3080220     DOI： 10.1002/1097-0142(19860315)57:6<1101::aid-cncr2820570606>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Thymomas. Current experience and future directions in therapy.

Authors:  P J Loehrer
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

2.  [High-dose methylprednisolone-containing chemotherapy in advanced invasive thymoma--report of three cases].

Authors:  T Suda; S Sugimura; Y Hattori; H Sugimura; Y Kobayashi; R Hoshino
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-01

Review 3.  Thymoma and thymic carcinoma.

Authors:  Federico Venuta; Erino A Rendina; Marco Anile; Tiziano de Giacomo; Domenico Vitolo; Giorgio F Coloni
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-01-13

4.  Clinical and pathologic predictors of survival in patients with thymoma.

Authors:  K B Wilkins; E Sheikh; R Green; M Patel; S George; M Takano; M Diener-West; J Welsh; S Howard; F Askin; G B Bulkley
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

5.  Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells.

Authors:  Yasunobu Funakoshi; Hiroyuki Shiono; Masayoshi Inoue; Yoshihisa Kadota; Mitsunori Ohta; Hikaru Matsuda; Meinoshin Okumura; Tadaaki Eimoto
Journal:  J Cancer Res Clin Oncol       Date:  2005-02-10       Impact factor: 4.553

Review 6.  Chemotherapy improves thymoma-associated graft-versus-host-disease-like erythroderma.

Authors:  Tatsuya Nagano; Yoshikazu Kotani; Kazuyuki Kobayashi; Nanako Tomita; Kyosuke Nakata; Akihiro Sakashita; Yasuhiro Funada; Hiroshi Nagai; Tomoo Itoh; Yoshihiro Nishimura
Journal:  BMJ Case Rep       Date:  2011-05-10

Review 7.  Remission of Thymoma on Steroid Therapy in a Patient With Atypical Thymoma-Associated Multiorgan Autoimmunity: A Case Report and Literature Review.

Authors:  Ewa Wrona; Sylwia Dębska-Szmich; Marta Pastuszka; Marcin Braun; Rafał Czyżykowski; Piotr Potemski
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

8.  Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Authors:  Lukas Kirzinger; Sandra Boy; Jörg Marienhagen; Gerhard Schuierer; Reiner Neu; Michael Ried; Hans-Stefan Hofmann; Karsten Wiebe; Philipp Ströbel; Christoph May; Julia Kleylein-Sohn; Claudia Baierlein; Ulrich Bogdahn; Alexander Marx; Berthold Schalke
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

9.  Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors.

Authors:  Anja C Roden; Sagar Rakshit; Geoffrey B Johnson; Sarah M Jenkins; Aaron S Mansfield
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

Review 10.  The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?

Authors:  Liliana Montella; Margaret Ottaviano; Rocco Morra; Erica Pietroluongo; Pietro De Placido; Marianna Tortora; Chiara Sorrentino; Gaetano Facchini; Sabino De Placido; Mario Giuliano; Giovannella Palmieri
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.